As of July 26 Clay Siegall the Chairman, President and Chief Executive Officer of Seattle Genetics, Inc reported a total of $95.4 million in their second quarter. The company sells anti-body drug conjugates (ADCs) in the pursuit of treating tumors associated with lymphomas. Notably ADCETRIS contributed $66.2 million of the total net sales. Siegall and Seattle Genetics, Inc are interested in promoting ADCETRIS to a major franchise of global proportions. It’s already available in 65 countries.
The company also reports that they have been successful with achieving five clinical trials for acute myeloid leukaemia (AML), moving to improve the survival of older patients. Along with AML, some ADCs for breast cancer are also moving towards clinical trials.
Clay B Siegall co-founded the Seattle Genetics, Inc in 1998. From his scientific background he brought his patient to help his patients by giving the company a foundation based on research, drug development and scientific innovation. Over 20 ADCs have been developed from the technology that Seattle Genetics provides.
From this the company has been able to generate over $675 million in revenue. $300 million of this revenue came from some the ADCs that the company has developed, including Pfizer, AbbVie and Genentech. Siegall has been recognized for building the oncology company successfully.
Siegall in 2013 was appointed to the Board of Directors of Mirna Therapeutics based on his success. He is working with the company to further the study of micro RNA based therapies in cancer research. Siegall has been recognized for his help in developing the successful Seattle Genetics, Inc as it pursues ADCs in the fight against tumor based cancers.